Subscribe To
BHC / Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
BHC News
By Zacks Investment Research
November 3, 2023
Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated
Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth. more_horizontal
By Accesswire
October 12, 2023
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results on Thurs more_horizontal
By Zacks Investment Research
September 21, 2023
Strength Seen in Bausch (BHC): Can Its 8.0% Jump Turn into More Strength?
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the st more_horizontal
By The Motley Fool
September 20, 2023
Why Bausch Health Stock Is Jumping Today
Bausch Health stock fell on Tuesday on the news of its CFO unexpectedly leaving. Wednesday brought a bounce as investors viewed the sell-off as a buyi more_horizontal
By The Motley Fool
September 19, 2023
Why Shares of Bausch Health Companies Fell Tuesday
Tom Vadaketh is leaving as Bausch's CFO after less than two years with the company. Vadaketh helped oversee financial improvement for Bausch. more_horizontal
By Market Watch
September 19, 2023
Bausch Health shares fall after CFO resignation
Bausch Health Cos. Inc. BHC, -1.76% shares fell nearly 3% premarket on Tuesday after the company announced late Monday that chief financial officer To more_horizontal
By InvestorPlace
September 19, 2023
7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom
There's a reason people are looking for cannabis stocks to buy now. It is increasingly likely that marijuana will be rescheduled from a Schedule I con more_horizontal
By Market Watch
September 18, 2023
Bausch Health CFO Tom Vadaketh to resign effective Oct. 13
Bausch Health finance chief Tom Vadaketh will resign effective Oct. 13 to pursue another opportunity, the Canadian pharmaceutical company said in a re more_horizontal